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Introduction: Cancer immunotherapy is a conceptually attractive
since it is highly specific and can deal with disseminated disease with
minimal impact on normal tissues. Early phase clinical trials have well
established the ability of a variety of immunotherapeutic approaches to
induce antigen specific immune responses in lung cancer patients.
Although no immunotherapy is likely to be a panacea, recent data from
randomized phase IIB studies offer promise of therapeutic activity in
both early and late stage lung cancer.
Methods: This report describes early clinical experience with vac-
cine 1650-G, an allogeneic cellular vaccine using granulocyte mac-
rophage colony stimulating factor as an adjuvant. This nonrandom-
ized pilot study was conducted at four sites in the Commonwealth of
Kentucky with primary objective of determining biological activity
in a relevant patient population; the use of similar antigen source,
immunization schedule, and immunological assessment facilitated
comparison to DC vaccines previously tested by our group.
Results: Data indicates 1650-G is safe and generated a robust and
unequivocal immunological response in 6/11 of immunized patients.
The relative frequency and kinetics of the response appears similar
to that achieved with DC vaccines (1650autologous DC). The fact
that this vaccine could be transported and delivered to cancer
patients in community cancer clinics also fulfills an important
objective of our research.
Conclusions: These findings provide critical foundation for further
testing of this simple, and comparatively inexpensive multivalent
NSCLC vaccine.
Key Words: Immunotherapy, Vaccines, Lung cancer, Clinical
trials.
(J Thorac Oncol. 2011;6: 169–173)
Based on poor therapeutic outcomes at all stages of lungcancer, investigating additional therapies that can consoli-
date responses to conventional therapy in unresectable non-
small cell lung cancer (NSCLC) and/or reduce risk of recurrence
after definitive surgical resection in earlier stage patients is
highly rational. Importantly, recent clinical results from three
randomized phase II clinical vaccine trials in NSCLC indicate a
perceptible therapeutic effect, providing additional momentum
to our own investigations of lung cancer vaccines.1–5 At present,
there are no comparative studies to suggest superiority of one
cancer vaccine agent, and relative biologic activity of various
vaccines is confounded by nonuniform study populations, dif-
fering vaccine formulations that incorporate a variety of anti-
gens, delivered at different doses, frequencies, and routes of
administration, and variable end points using multiple means of
immune assessment.1,6 Nonetheless, at the current level of ma-
turity in the field, immunologic parameters provide the best
relative measure of potency, especially during developmental
phases of a vaccine. Although it must be emphasized that
immunologic response is not a surrogate for therapeutic efficacy,
multiple immunotherapy studies have observed an association of
clinical response and induced immunity.1,5,7–13 In context, the abil-
ity of most vaccines to induce measurable immunologic responses
suggests that many vaccines could have similar efficacy.
Assuming that the potential for therapeutic efficacy
depends more on the ability of an agent to induce an immu-
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Statement of translational relevance: Based on poor therapeutic outcomes at
all stages of lung cancer, investigating additional therapies that can
consolidate responses to conventional therapy in unresectable NSCLC
and/or reduce risk of recurrence after definitive surgical resection in
earlier stage patients is highly rational. Cancer vaccines are an additional
modality, with low risk of complications that may benefit either popu-
lation. Our research objectives have been to develop and test a compar-
atively inexpensive, nonproprietary multivalent lung cancer vaccine that
can be practically studied in advanced phase investigation. Proving
therapeutic efficacy is an overarching objective; a secondary goal is to
further support the central precept that immunological response to rele-
vant antigens correlates with clinical benefit irrespective of the specific
agent. As we proceed, we intend to better define the clinical significance
of immunological response to vaccines, to use immunological parameters
to define reasons for therapeutic effect or treatment failures, to optimize,
and to ultimately rationally implement of cancer vaccines as a standard
part of lung cancer therapy.
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nologic response than on any specific vaccine formulation or
adjuvant used, we produced a multivalent NSCLC vaccine using
the allogeneic NSCLC cell line 1650 plus recombinant granu-
locyte macrophage colony stimulating factor (GMCSF) (1650-
G). Pilot investigation measured immunologic responses to
1650-G in 11 patients with stage I/II NSCLC with no evidence
of disease after surgical resection; dendritic cell (DC) vaccines
tested in 36 patients with NSCLC at the University of Kentucky
served as a historical benchmark for biologic activity.14,15 Facil-
itating the comparison, 1650-G uses the same source of antigen,
immunization schedule, and immunologic analysis as the previ-
ously tested DC vaccines.
PATIENTS AND METHODS
Human Subjects/Patient Characteristics
Individuals with histologically confirmed stages I to IIB
NSCLC who had completed definitive surgical or multimo-
dality therapy and had stable clinical disease at screening
were eligible for the study. Individuals were eligible to enter
the study anytime from 4 weeks to 6 months after surgical
resection. Immune deficiency including use of immunosup-
pressive steroids (chronic or intermittent) was part of exclu-
sion criteria. Twelve participants accrued during 2-year time
frame were consented under Institutional Review Board-
approved protocols; one subject withdrew before completing
the study. Patient characteristics are summarized in Table 1.
Trial Design
The study was conducted at four study sites in the
Commonwealth of Kentucky. The trial was nonrandomized.
Measurable immunologic response to vaccine was the pri-
mary end point. Comparative immunologic data were central
to the study. Developing collaborative infrastructure and
determining practicality of delivering cancer vaccines at com-
munity cancer centers within the Commonwealth of Ken-
tucky was a major interest. Small sample size and patient
heterogeneity would preclude meaningful assessment of ther-
apeutic effects. Clinical tolerability was determined by rou-
tine safety laboratories and clinical events described by the
National Cancer Institute, Cancer Therapy Evaluation Pro-
gram, Common Terminology Criteria for Adverse Events.
Vaccine Formulation
1650-G comprises an apoptosed and lethally irradiated
tumor cell allogeneic line and GMCSF (Berlex Inc., Rich-
mond, CA). The dose of GMCSF delivered with each vaccine
(100 g) is intended to induce only local immune cell
stimulation; this amount is a fraction of the recommended
clinical dose used to stimulate bone marrow proliferation
(250 g/m2/d delivered subcutaneously or intravenously for
up to 42 consecutive days). The lung tumor cell line 1650 is
known to overexpress Her-2/neu, carcinoembryonic antigen,
Mage 2, WT-1, survivin, and New York esophageal squa-
mous cell carcinoma 1 antigen.14,15 This combination of
antigen assures that more than 98% of all NSCLC will
express at least one of these dominant antigens, possibly
more, and likely a number of minor antigenic determinants.
The line is major histocompatibility complex (MHC) class I
haplotype human leukocyte antigen-A2, B15, and C7; it is
MHC class II negative. This is the same antigen source used
in previously described DC vaccines delivered to a series of
36 individuals with NSCLC.14,15 Prepared vaccines were
stored in vials containing 1.12  108 and 116 g of GMCSF
in 0.7 ml sterile saline in the gas phase of liquid nitrogen until
delivery.
Immunization Protocol
A prime vaccine and a single boost were given 1 month
apart. Each immunization delivered 1.0  108 processed
1650 tumor cells plus 100 g GMCSF in 0.6 ml volumes;
vaccine was injected intradermally at two locations in the
thigh (0.3 ml/injection, 0.6 ml total); opposite thighs were
used for prime and boost vaccine. Patients were monitored in
the outpatient clinic for 30 minutes after immunization for
immediate unanticipated adverse events.
TABLE 1. Patient Characteristics
Patient Age (yr) Smoking Histology Stage
Adjuvant Treatment
(Yes/No)
Surgery to First
Immunization (mo)
Immune Response
(Yes/No)
1 85 F Squamous cell Stage II (T2N1M0) No 3 Y
2 69 F Adenocarcinoma Stage I (T2N0M0) No 6 Y
3 69 F Adenocarcinoma Stage I (T2N0M0) No 2 Y
4 60 A Adenocarcinoma Stage I (T2N0M0) No 4 N
5a 46 F Adenocarcinoma Stage I (T2N0M0) No 2
6 71 F Squamous cell Stage I (T1N0M0) No 2 N
7 76 A Large cell Stage I (T2N0M0) Yes (radiation) 5 Y
8b 72 F Squamous cell Stage II (T2N1M0) No 4 N
9 70 F Squamous cell Stage I (T1N0M0) No 1 Y
10 68 A Large cell Stage I (T1N0M0) No 3 Y
11 74 A Squamous cell Stage I (T1N0M0) No 4 N
12 56 A Large cell Stage I (T1N0M0) No 6 N
a Subject withdrew before completion of study protocol.
b Subject was discontinued from study based on documented disease recurrence.
A, active; F, former; N, never.
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Clinical Evaluation
Follow-up by primary treating physicians included rou-
tine history and physical, chest x-ray, and/or computed to-
mography scans at regular intervals posttherapy or as directed
by signs or symptoms of tumor recurrence. Routine chemis-
tries and complete blood count with differentials were drawn
4 weeks after each of the two immunizations.
Immunologic Assessment
Serial blood samples were drawn for immunologic
testing (prevaccine, week 1, week 4, week 5, week 8, week
12, and week 16 to complete the initial series; samples were
also drawn at 6 and 12 months postvaccine). Peripheral blood
mononuclear cells (PBMCs) were isolated using standard
Ficoll Hypaque separation and expanded using phytohemag-
glutinin (PHA; 5 g/ml  10 days) as described previou-
sly.14,15 PHA expansion was done to assure adequate numbers
of cells for immunologic analysis; previous comparative
studies show results using PHA stimulated are comparable
with those using unstimulated PBMC.14,15 IFN- ELISPOT
assays were performed using 1650-antigen pulsed autologous
DCs as targets for immune reactivity; autologous DCs were
derived from each individual’s peripheral blood drawn pre-
immunization and cultured in 5% allogeneic heat inactivated
AB serum. Assay controls included DCs  PBMC and
PBMC alone as described previously.14,15 PHA-stimulated
normal donor PBMCs were used as positive control in all
assays. Assays were performed in triplicate.
RESULTS
Adverse Events
All subjects noted mild to moderate erythema and
induration at the injection sites lasting up to 14 days postim-
munization. There were no other adverse events related to the
vaccine. Safety laboratories checked after immunization re-
vealed no abnormalities in hematological parameters or se-
rum chemistries. There was no indication in these studies that
the GMCSF component of the vaccine stimulated bone mar-
row proliferation.
Immunologic Response
Interferon (IFN) enzyme-linked immunosorbent spot
(ELISPOT) assay was performed at all available time points in
the 11 individuals who completed the immunization protocol.
Measurements were made of the number of IFN--producing
lymphocytes (spots) in 24 hours culture with 1650-antigen
pulsed autologous DC targets produced from a prevaccine blood
draw. Controls included lymphocytes plus DC without antigen
and lymphocytes alone. Comparisons were made between each
postvaccine measurement and the prevaccine response for each
condition. Comparisons were also made between conditions at
individual time points (1650-pulsed DC targets versus controls).
Six of 11 individuals met the following definition of immuno-
logic response: more than fivefold increase in number of spots
from prevaccine baseline and more than fivefold increase above
respective controls at any available time point after prime im-
munization (1–16 weeks postvaccine). These six response pro-
files are shown in Figure 1; raw data are expressed as the
absolute number of lymphocytes producing IFN- (spots) in
response to stimulation with 1650-pulsed autologous DCs or
controls (DCs without antigen plus lymphocytes and lympho-
cytes alone). Prevaccine baselines ranged from 0 to 4 spots. Peak
1650-specific reactions ranged from 27  3 to 143  13 spots.
With one exception (patient 1 week 16), control measurements
at all time points ranged from 0 to 2. Patterns of reactivity varied
between individuals. Of the six observed responses, three were
biphasic and three showed only one dominant peak. Peak reac-
tions were seen at 1 or 4 weeks post prime and/or boost
immunization, were measurable above baseline for 4 to 12
weeks, and returned to baseline by 24 weeks. Five of 11
individuals showed neither significant increases in number of
spots above baseline to 1650-pulsed DC targets nor increases
above controls (not shown). There were no specific patient
characteristics that correlated with response.
Clinical Outcomes
Clinical end points were not a study objective. Clin-
ical follow-up is, however, available on all individuals
who completed the immunization protocol for 12 months
from primary immunization. One of 12 individuals was
identified as having disease recurrence 4 months after the
second of two immunizations and died 16 months later.
That particular individual did not have an immunologic
response to vaccine.
DISCUSSION
Our interest in producing and testing 1650-G is to
expand on previous work with DC vaccines for lung can-
cer.14,15 Those data show that autologous DCs pulsed with an
allogeneic cell line that expresses a complement of tumor
antigens (1650) clearly induce immune responses in a per-
centage of patients, performing comparably to, if not better
than, most other solid tumor vaccines.16 Assuming vaccines
that induce immunologic response have the highest potential
to be clinically efficatious, we might predict that these vac-
cines would be therapeutically active in advanced phase
investigation. Problematically, DC vaccine production is pro-
tracted, resource intensive, and costly, making this approach
impractical for phase III studies and/or broad clinical use.
With the objective of making an economical, transportable,
“off the shelf” NSCLC vaccine, we have designed a vaccine
(1650-G) that combines the processed antigen component of
our DC vaccine (tumor cell line 1650) with the recombinant
GMCSF as an immune adjuvant. This study was designed
with primary objective of determining biologic activity in a
relevant patient population; the use of similar antigen source,
immunization schedule, and immunologic assessment facili-
tated comparison with DC vaccines previously tested by our
group. Determining practicality of delivering cancer vaccines
at community cancer centers across the Commonwealth of
Kentucky was also a major interest.
Data show that 1650-G generated a robust and unequiv-
ocal immunologic response in 6 of 11 immunized patients.
The relative frequency and kinetics of the response seem
similar to that achieved with DC vaccines tested at the
University of Kentucky, although small study numbers pre-
clude statistical correlation. The fact that this vaccine could
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be transported and delivered to patients with cancer in re-
gional cancer clinics in rural Kentucky also fulfills an impor-
tant objective of our research.
From the current immunologic data, we can only de-
duce information about vaccine potency and immune com-
petence of the subjects. Although multiple immunotherapy
studies have observed an association of clinical response and
induced immunity, measureable immune responses are nei-
ther a surrogate nor likely to be predictive of clinical re-
sponse.5,7–13,17 Independent of myriad local and systemic
barriers to antitumor effect not accounted for by standard
immune monitoring, correlation of immune parameters and
clinical response has been hampered by nonuniform assay
techniques, variable clinical response criteria, and low statis-
tical power of clinical trials.6,17 Notwithstanding the uncer-
tain clinical significance of immunologic assays, collective
literature would support the probability that multiple agents
that achieve similar immune induction to relevant antigens
have similar potential for therapeutic efficacy. As such, es-
tablished immunologic assays are important tools for rational
vaccine development, testing, and comparative analysis. Us-
ing DC vaccines as a standard for further vaccine develop-
ment, this finding provides critical foundation for further
testing of this multivalent NSCLC vaccine. Admittedly, there
remains a gap between biologic and therapeutic activity that
must be resolved; however, in context of encouraging ran-
domized and nonrandomized phase II efficacy data that high-
light the association of immune induction and clinical re-
sponse criteria, and the initiation of phase III studies with
four other lung cancer vaccines, we assert the need for related
investigation is highly rational and timely. We view 1650-G
as a biologically reliable and comparatively inexpensive,
universal preparation, and one very likely to have equal
therapeutic activity to other more complex and proprietary
vaccines.
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FIGURE 1. Interferon (IFN-) enzyme-linked immunosorbent spot assay: raw data from each of the six patients showing an
immunologic response to vaccine as defined by more than fivefold increase in number of spots from prevaccine baseline and
more than fivefold increase above respective time point controls (dendritic cell [DC]  peripheral blood mononuclear cell
[PBMC] and PBMC alone) at any available time point after prime immunization (1–16 weeks postvaccine). The “number of
spots” reflects the absolute number of lymphocytes producing IFN- in response to stimulation with (F)1650-pulsed autolo-
gous DCs, (f) DCs without antigen plus lymphocytes, or (E) lymphocytes alone. Arrows indicate time of vaccine delivery.
Each point represents the mean of triplicate measurements  standard.
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